Page 81 - AN-1-2

Advanced Neurology NMDA receptors in neuropsychiatric diseases

amyloid precursor protein expression pattern and increases like dopamine release abnormalities in a mouse model of
amyloid-ss production. J Neurosci, 30: 15927–15942. NMDA receptor hypofunction. Schizophr Bull, 45: 138–147.
https://doi.org/1523/JNEUROSCI.3021-10.2010 https://doi.org/1093/schbul/sby003
218. Lai TW, Shyu WC, Wang YT, 2011, Stroke intervention 229. Coyle JT, Tsai G, Goff D, 2003, Converging evidence of
pathways: NMDA receptors and beyond. Trends Mol Med, NMDA receptor hypofunction in the pathophysiology of
17: 266–275. schizophrenia. Ann N Y Acad Sci, 1003: 318–327.
https://doi.org/1016/j.molmed.2010.12.008 https://doi.org/1196/annals.1300.020
219. Dunah AW, Wang Y, Yasuda RP, et al., 2000, Alterations 230. Javitt DC, Zukin SR, 1991, Recent advances in the
in subunit expression, composition, and phosphorylation phencyclidine model of schizophrenia. Am J Psychiatry,
of striatal N-methyl-D-aspartate glutamate receptors in a 148: 1301–1308.
rat 6-hydroxydopamine model of Parkinson’s disease. Mol
Pharmacol, 57: 342–352. https://doi.org/1176/ajp.148.10.1301
220. Gardoni F, Picconi B, Ghiglieri V, et al., 2006, A critical 231. Krystal JH, Karper LP, Seibyl JP, et al., 1994, Subanesthetic
interaction between NR2B and MAGUK in L-DOPA effects of the noncompetitive NMDA antagonist, ketamine,
induced dyskinesia. J Neurosci, 26: 2914–2922. in humans. Psychotomimetic, perceptual, cognitive,
and neuroendocrine responses. Arch Gen Psychiatry,
https://doi.org/1523/JNEUROSCI.5326-05.2006 51: 199–214.
221. Mony L, Kew JN, Gunthorpe MJ, et al., 2009, Allosteric https://doi.org/1001/archpsyc.1994.03950030035004
modulators of NR2B-containing NMDA receptors:
Molecular mechanisms and therapeutic potential. Br J 232. Koek W, Woods JH, Winger GD, 1988, MK-801, a proposed
Pharmacol, 157: 1301–1317. noncompetitive antagonist of excitatory amino acid
neurotransmission, produces phencyclidine-like behavioral
https://doi.org/1111/j.1476-5381.2009.00304.x
effects in pigeons, rats and rhesus monkeys. J Pharmacol
222. Sgambato-Faure V, Cenci MA, 2012, Glutamatergic Exp Ther, 245: 969–974.
mechanisms in the dyskinesias induced by pharmacological 233. Kovacic P, Somanathan R, 2010, Clinical physiology and
dopamine replacement and deep brain stimulation for the mechanism of dizocilpine (MK-801): Electron transfer,
treatment of Parkinson’s disease. Prog Neurobiol, 96: 69–86.
radicals, redox metabolites and bioactivity. Oxid Med Cell
https://doi.org/1016/j.pneurobio.2011.10.005 Longev, 3: 13–22.
223. Gardoni F, Sgobio C, Pendolino V, et al., 2012, Targeting https://doi.org/4161/oxim.3.1.10028
NR2A-containing NMDA receptors reduces L-DOPA- 234. Dalmau J, Lancaster E, Martinez-Hernandez E, et al., 2011,
induced dyskinesias. Neurobiol Aging, 33: 2138–2144.
Clinical experience and laboratory investigations in patients
https://doi.org/1016/j.neurobiolaging.2011.06.019 with anti-NMDAR encephalitis. Lancet Neurol, 10: 63–74.
224. Nakazawa K, Sapkota K, 2020, The origin of NMDA https://doi.org/1016/S1474-4422(10)70253-2
receptor hypofunction in schizophrenia. Pharmacol Ther,
205: 107426. 235. 1993, A novel gene containing a trinucleotide repeat
that is expanded and unstable on Huntington’s disease
https://doi.org/1016/j.pharmthera.2019.107426 chromosomes. The Huntington’s Disease Collaborative
225. Howes OD, Kapur S, 2009, The dopamine hypothesis of Research Group. Cell, 72: 971–983.
schizophrenia: version III--the final common pathway. https://doi.org/1016/0092-8674(93)90585-e
Schizophr Bull, 35: 549–562.
236. Fan MM, Raymond LA, 2007, N-methyl-D-aspartate
https://doi.org/1093/schbul/sbp006 (NMDA) receptor function and excitotoxicity in
226. Moghaddam B, Javitt D, 2012, From revolution to Huntington’s disease. Prog Neurobiol, 81: 272–293.
evolution: the glutamate hypothesis of schizophrenia and https://doi.org/1016/j.pneurobio.2006.11.003
its implication for treatment. Neuropsychopharmacology,
37: 4–15. 237. Milnerwood AJ, Gladding CM, Pouladi MA, et al.,
2010, Early increase in extrasynaptic NMDA receptor
https://doi.org/1038/npp.2011.181 signaling and expression contributes to phenotype onset in
227. Mohn AR, Gainetdinov RR, Caron MG, et al., 1999, Mice Huntington’s disease mice. Neuron, 65: 178–190.
with reduced NMDA receptor expression display behaviors https://doi.org/1016/j.neuron.2010.01.008
related to schizophrenia. Cell, 98: 427–436.
238. Okamoto S, Pouladi MA, Talantova M, et al., 2009, Balance
https://doi.org/1016/s0092-8674(00)81972-8
between synaptic versus extrasynaptic NMDA receptor
228. Nakao K, Jeevakumar V, Jiang SZ, et al., 2019, Schizophrenia- activity influences inclusions and neurotoxicity of mutant

Volume 1 Issue 2 (2022) 25 https://doi.org/10.36922/an.v1i2.148